三阴性乳腺癌 (TNBC) 由于缺乏 ER、PR 和 HER2 受体而以其侵袭性和治疗挑战而闻名。我们的工作强调了 LCP1（淋巴细胞胞质蛋白 1）的预后价值，它在细胞过程和免疫细胞活动中发挥着至关重要的作用，可以预测 TNBC 的结果并指导治疗。我们探索了 LCP1 作为 TNBC 的潜在生物标志物，并研究了 mRNA和LCP1的蛋白表达水平。我们研究了不同的数据库，包括 GTEX、TCGA、GEO、cBioPortal 和 Kaplan-Meier Plotter。对 TNBC 和良性肿瘤样本进行免疫组织化学检查 LCP1 与患者临床特征和巨噬细胞标记物的关系。我们还使用各种生物信息学工具评估了与LCP1相关的存活率、免疫细胞浸润和药物敏感性。结果表明，与邻近正常组织相比，TNBC组织中LCP1的表达较高。然而，LCP1 的高表达与 TNBC 患者的良好生存结果显着相关。富集分析表明，与LCP1共表达的基因在各种免疫过程中显着富集。 LCP1与静息树突状细胞、M1巨噬细胞和记忆CD4 T细胞的浸润呈正相关，与M2巨噬细胞呈负相关。进一步的分析表明，高水平的 LCP1 与接受免疫治疗的癌症患者的生存结果增加之间存在联系。LCP1 可能作为 TNBC 的潜在诊断和预后生物标志物，它与免疫细胞浸润密切相关，特别是 M1 和 M2 巨噬细胞。我们的研究结果可能为 TNBC 患者的免疫治疗策略提供有价值的见解。© 2024。作者。

Triple-Negative Breast Cancer (TNBC) is known for its aggressiveness and treatment challenges due to the absence of ER, PR, and HER2 receptors. Our work emphasizes the prognostic value of LCP1 (Lymphocyte cytosolic protein 1), which plays a crucial role in cell processes and immune cell activity, to predict outcomes and guide treatments in TNBC.We explored LCP1 as a potential biomarker in TNBC and investigated the mRNA and protein expression levels of LCP1. We investigated different databases, including GTEX, TCGA, GEO, cBioPortal and Kaplan-Meier Plotter. Immunohistochemistry on TNBC and benign tumor samples was performed to examine LCP1's relationship with patient clinical characteristics and macrophage markers. We also assessed survival rates, immune cell infiltration, and drug sensitivity related to LCP1 using various bioinformatics tools.The results indicated that LCP1 expression was higher in TNBC tissues compared to adjacent normal tissues. However, high expression of LCP1 was significantly associated with favorable survival outcomes in patients with TNBC. Enrichment analysis revealed that genes co-expressed with LCP1 were significantly enriched in various immune processes. LCP1 showed a positive correlation with the infiltration of resting dendritic cells, M1 macrophages, and memory CD4 T cells, and a negative correlation with M2 macrophages. Further analysis suggested a link between high levels of LCP1 and increased survival outcomes in cancer patients receiving immunotherapy.LCP1 may serve as a potential diagnostic and prognostic biomarker for TNBC, which was closely associated with immune cell infiltration, particularly M1 and M2 macrophages. Our findings may provide valuable insights into immunotherapeutic strategies for TNBC patients.© 2024. The Author(s).